Soricimed - NBIF - FINB
Français
Close

Paul
Gunn

Soricimed

President & CEO

Soricimed
Soricimed

Investment
$250,000

Industry
Bio-tech

Founded
2005

Soricimed Biopharma is a clinical stage drug development company dedicated to novel targeted treatments for cancer.

Soricimed Biopharma is a private, clinical-stage biopharmaceutical company focused on developing proprietary first-in-class targeted cancer therapies, peptide-drug conjugates and a companion diagnostic. They have been successful in translating their initial discovery of soricidin, a protein from the venom of the Northern Short-Tailed Shrew, into new drug candidates for the treatment of various solid tumour cancers.

Soricimed has completed a multi-centre phase 1 clinical trial in Canada and the United States and been granted Orphan Drug Status for ovarian and pancreatic cancer.  The company has raised over $20M to date between Equity ($11M) and government ($9M) funding.